Medication info
Dronel Plus Tablet

Dronel Plus Tablet

Prescription medicationTabletOral
Ingredient · strength
Risedronate Sodium 2.5 Hydrate›40.162mg / 1 tabletCholecalciferol Concentrate Powder›56mg / 1 tablet
Manufacturer / importer
Hanin Pharmaceutical Co., Ltd.
Appearance
Light orange oval film-coated tablet
Packaging
4 tablets/PTP
Approval status
Active

MFDS item code 201604117 · Approved 2016.06.30 · Insurance code 657202890

Summary

Main use
Treatment and prevention of osteoporosis in postmenopausal women; treatment of osteoporosis in men
Who takes it
Adults · Children
Adult dose
Adults: Administer 1 tablet orally once weekly. Elderly patients: Since the bioavailability and pharmacokinetics of this drug in elderly patients (60 years of age or older) are similar to those in younger people, no dose adjustment is necessary. Patients with renal impairment: No dose adjustment is required for patients with creatinine clearance of 30ml/min or higher. This drug is contraindicated in patients with severe renal impairment with creatinine clearance below 30ml/min. Since food interferes with the absorption of this drug, take it as follows to ensure adequate absorption. Take it at least 30 minutes before breakfast, or at least 2 hours before or after consuming food or beverages at any time during the day. To help this drug reach the stomach easily and reduce the possibility of esophageal irritation, take it in an upright position with a sufficient amount of plain water (170 ~ 230ml). Taking this drug with other beverages, including mineral water, may reduce its absorption. Do not chew or suck this drug because of the possibility of oropharyngeal ulceration. Patients should also remain upright for at least 30 minutes after taking the drug. Patients should take supplements if their dietary intake of calcium and vitamin D is inadequate. Patients at high risk of vitamin D deficiency (e.g., patients over 70 years of age, patients in nursing homes, and patients with chronic diseases) may require additional vitamin D supplementation. Patients with gastrointestinal malabsorption syndromes may require higher doses of vitamin D supplements, and measurement of 25-hydroxyvitamin D levels should be considered. The recommended daily intake of vitamin D is 400 IU to 800 IU. This drug, taken once weekly, provides a week's supply at 800 IU of vitamin D daily. If a patient forgets to take the drug on the scheduled day, take it on the day it is remembered. Resume the usual schedule for the next dose. Do not take 2 tablets on the same day.
Child dose
Children: Safety and efficacy have not been established in children and growing adolescents.

Ingredients

Manufacturer
Hanin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment and prevention of osteoporosis in postmenopausal women; treatment of osteoporosis in men

  • Osteoporosis
View approved original text

Used for the treatment and prevention of osteoporosis in postmenopausal women and men.

How to take

Adult dose

Adults: Administer 1 tablet orally once weekly. Elderly patients: Since the bioavailability and pharmacokinetics of this drug in elderly patients (60 years of age or older) are similar to those in younger people, no dose adjustment is necessary. Patients with renal impairment: No dose adjustment is required for patients with creatinine clearance of 30ml/min or higher. This drug is contraindicated in patients with severe renal impairment with creatinine clearance below 30ml/min. Since food interferes with the absorption of this drug, take it as follows to ensure adequate absorption. Take it at least 30 minutes before breakfast, or at least 2 hours before or after consuming food or beverages at any time during the day. To help this drug reach the stomach easily and reduce the possibility of esophageal irritation, take it in an upright position with a sufficient amount of plain water (170 ~ 230ml). Taking this drug with other beverages, including mineral water, may reduce its absorption. Do not chew or suck this drug because of the possibility of oropharyngeal ulceration. Patients should also remain upright for at least 30 minutes after taking the drug. Patients should take supplements if their dietary intake of calcium and vitamin D is inadequate. Patients at high risk of vitamin D deficiency (e.g., patients over 70 years of age, patients in nursing homes, and patients with chronic diseases) may require additional vitamin D supplementation. Patients with gastrointestinal malabsorption syndromes may require higher doses of vitamin D supplements, and measurement of 25-hydroxyvitamin D levels should be considered. The recommended daily intake of vitamin D is 400 IU to 800 IU. This drug, taken once weekly, provides a week's supply at 800 IU of vitamin D daily. If a patient forgets to take the drug on the scheduled day, take it on the day it is remembered. Resume the usual schedule for the next dose. Do not take 2 tablets on the same day.

Child dose

Children: Safety and efficacy have not been established in children and growing adolescents.

Precautions

This medicine may irritate the gastrointestinal mucosa, potentially causing esophageal adverse reactions such as esophagitis and esophageal ulcers. Take with a sufficient amount of water, and do not lie down for at least 30 minutes after taking. If you have issues with the esophagus or experience symptoms such as difficulty swallowing, pain behind the sternum, or heartburn, stop taking immediately and consult a doctor. This medicine should not be administered to patients with esophageal strictures that delay esophageal emptying, those allergic to any component of this medicine, patients with hypocalcemia, or those with severely impaired renal function. Patients with hypersensitivity to Yellow No. 5 should use this medicine with caution. During treatment with this medicine, side effects such as indigestion, nausea, diarrhea, muscle pain, joint pain, headache, or rash may occur, and rarely, serious skin reactions, osteonecrosis of the jaw, or liver function abnormalities have been reported. Metabolic disorders such as hypocalcemia and vitamin D deficiency should be treated before initiating therapy, and it is important to consume adequate calcium and vitamin D. This medicine may be affected by food or medications containing calcium, magnesium, or iron, so it is important to maintain dosing intervals. Women who are pregnant or nursing should avoid taking this medicine, and safety in children has not been established. In cases of overdose, hypocalcemia may occur, and gastric lavage or calcium supplement therapy may be necessary. This medicine should be kept out of reach of children and should not be transferred to another container.

Side effects

  • Esophagitis
  • esophageal ulcer
  • esophageal erosion
  • esophageal obstruction
  • perforation
  • hemorrhage
  • gastric ulcer
  • duodenitis
  • stomatitis
  • hypocalcemia
Show 84 more
  • hypophosphatemia
  • bone pain
  • joint pain
  • muscle pain
  • depression
  • dizziness
  • insomnia
  • anxiety
  • neuralgia
  • vertigo
  • tension headache
  • sensory disturbances
  • pharyngitis
  • rhinitis
  • dyspnea
  • pneumonia
  • rash
  • pruritus
  • skin cancer
  • cataract
  • conjunctivitis
  • otitis media
  • urinary tract infection
  • cystitis
  • injury due to accident
  • epidemic cold syndrome
  • headache
  • overdose
  • allergic reaction
  • syncope
  • vasodilation
  • constipation
  • dyspepsia
  • nausea
  • diarrhea
  • gastroenteritis
  • bloating
  • colitis
  • vomiting
  • thirst
  • peripheral edema
  • traumatic fracture
  • myalgia
  • arthritis
  • bursitis
  • bronchitis
  • sinusitis
  • increased cough
  • fever
  • falling
  • dizziness
  • increased serum alkaline phosphatase
  • facial edema
  • alopecia
  • atypical olfaction
  • heartburn
  • epigastric pain
  • loss of appetite
  • weakness
  • chest discomfort
  • palpitations
  • increased sweating
  • burning sensation
  • kidney stones
  • belching
  • hematuria
  • fever
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • angioedema
  • blister
  • jawbone necrosis
  • liver dysfunction
  • jaundice
  • external auditory canal osteonecrosis
  • hypocalcemia
  • hypercalcemia
  • hypercalciuria
  • loss of appetite
  • nausea
  • vomiting
  • polyuria
  • frailty
  • drowsiness

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly sealed container to prevent air or moisture from entering. Additionally, it should be stored at room temperature, between 1 and 30 degrees Celsius, avoiding extremes in temperature.

Appearance and packaging

Appearance

Light orange oval film-coated tablet

Package unit

4 tablets/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.